Alzheimer's Memory Loss Reversed By Wearable Head Device

Rate this article

Rate this article

brain with alzheimer's disease
  • A wearable head device that emits electromagnetic waves has shown promise in reversing memory impairment associated with Alzheimer's disease.
  • A small trial of 8 people found that the Transcranial Electromagnetic Treatment (TEMT) resulted in improved cognition, word recall, and memory.
  • MRI bran scans showed increased communication between neurons involved with cognition.
  • TEMT likely works by easily penetrating brain cells to break up aggregates of A-beta and tau, both of which are toxic proteins for Alzheimer's disease.

This article was published on EurekAlert.org.

New results in the Journal of Alzheimer's Disease indicate that in-home treatment with a bioengineered head device emitting electromagnetic waves reversed memory impairment of Alzheimer's patients (AD).

There is finally some encouraging news for the millions of Americans suffering from Alzheimer's Disease. NeuroEM Therapeutics today announced findings from an open label clinical trial showing reversal of cognitive impairment in Alzheimer's Disease patients after just two months of treatment using the company's wearable head device for in-home treatment.

Results demonstrate that TEMT was safe in all eight participating patients with mild to moderate AD and enhanced cognitive performance in seven of them, as measured by their ADAS-cog score, which is the benchmark for testing AD therapeutics. The study is being published in the new issue of the Journal of Alzheimer's Disease.

The investigators had previously demonstrated that treating AD mice with electromagnetic waves in the radiofrequency range resulted in protection against memory impairment in young AD mice and reversal of memory impairment in aged AD mice.

For the present clinical study in humans, the investigators used the same treatment (twice daily for 1-hour) through creation of NeuroEM's first-in-class MemorEMTM head device. The device has multiple, highly-specialized emitters positioned within a head cap that are activated sequentially, with treatments easily administered in-home by the patient's caregiver. As well, the device allows for near complete mobility to perform nearly all household activities during treatments.

"Perhaps the best indication that the two months of treatment was having a clinically-important effect on the AD patients in this study is that none of the patients wanted to return their head device to the University of South Florida/Byrd Alzheimer's Institute after the study was completed", said Dr.Gary Arendash, CEO of NeuroEM Therapeutics. One patient even exclaimed "I've come back."

The investigators indicated they have strong evidence that TEMT is directly affecting the Alzheimer's disease process by easily penetrating the brain and brain cells to break up aggregates of two toxic proteins inside brain cells called A-beta and tau.

TEMT's ability to disaggregate both toxic proteins inside brain cells (neurons) appears to be key to stopping and reversing the cognitive loss of AD. Present AD drugs in clinical trials have great difficulty getting into the brain and then into brain cells. Even if they succeeded in doing so, they do not yet have the capacity to target the small aggregates of A-beta and tau proteins that appear to be causative to AD.

NeuroEM Therapeutics is planning for a pivotal clinical trial to begin recruitment of approximately 150 mild/moderate AD subjects later this year for treatment with the company's MemorEMTM device. If that trial shows continued safety and cognitive benefits, NeuroEM Therapeutics plans to ask the FDA for approval of the MemorEM device for treatment of AD. The clinical locations for this multi-site trial have not yet been determined.

"Despite significant efforts for nearly 20 years, stopping or reversing memory impairment in people with Alzheimer's disease has eluded researchers," said co-author Amanda Smith, M.D., Director of Clinical Research, University of South Florida Health, Byrd Alzheimer's Institute, the clinical center for the study. "These results provide preliminary evidence that TEMT administration we assessed in this small AD study may have the capacity to enhance cognitive performance in patients with mild to moderate disease."

After two months of treatment administered at home by their caregivers, none of the eight patients in the study exhibited any deleterious side effects on behavior or physiologic measures, as recorded by caregivers in daily diaries. Moreover, post-treatment brain scans revealed no visible induction of tumors or brain bleedings called microhemorrhages.

Using the benchmark ADAS-cog task to assess a variety of cognitive measures, seven of the eight AD patients collectively responded to treatment with a 4+ point increase in cognitive performance by the end of the 2-month treatment period -- the results indicate a very large and clinically-important effect.

Since AD patients typically show a 4+ point decline in ADAS-cog performance over a given one year period, the 4+ point improvement provided by TEMT was as if the treated patients had gone back in time to their better cognitive performance of one year earlier.

"We were particularly surprised that this highly significant improvement in the ADAS-cog was maintained even two weeks after treatment was completed", stated Dr. Arendash. "The most likely explanation for continued benefit after cessation of treatment is that the Alzheimer's Disease process itself was being affected.

Cognitive abilities were improved in other tasks as well, such as the Rey AVLT task, wherein clinically important increases in word recall were present after treatment for 2 months and at two weeks thereafter. Even a 50% reduction in forgetting was observed in this important task.

In addition to cognitive assessment, the study also involved analysis of AD markers in both the blood and the cerebrospinal fluid (CSF) before and at the end of the 2-month treatment period. These AD markers were changed in directions expected for TEMT disaggregating the two toxic proteins (A-beta and tau) that appear to be the disease's root causes.

Also, MRI brain scans in individual AD patients revealed evidence of increased communication between neurons in a brain area critical for cognitive integration called the cingulate cortex/cingulum.

The investigators believe that TEMT may be an entirely new therapeutic intervention against Alzheimer's disease and that NeuroEM's bioengineering technology may be succeeding where drug therapy against this devastating disease has thus far failed.

Based on the findings and the enthusiasm for continued treatment that all patients expressed, patients were offered and accepted continued TEMT in a now on-going extension study averaging 17 months between initial study start and extension study finish. More information about both the completed and on-going clinical trials is available at NeuroEM's website.

The open-label study was a single center, single arm trial in eight patients 63 years of age and older with mild to moderate Alzheimer's disease (AD) to evaluate the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT). Patients were enrolled at the University of South Florida Health/Byrd Alzheimer's Institute, which also conducted most clinical study assessments. Treatment was administered in the patient's home by a caregiver (spouse, relative), using the MemorEM device.

Patients received TEMT for one-hour periods twice daily for two months. Although limitations of this study include the small number of subjects, not having a control group, and being of relatively short treatment duration, 120 treatments were administered in-home and the cognitive benefits observed were clinically important/meaningful at the highest levels. Providing additional credibility to the observed cognitive enhancements were the beneficial changes in AD markers in blood and CSF, as well as the enhancement in brain MRI imaging.

This study was authored by Gary Arendash, Ph.D., and published in Journal of Alzheimer's Disease in September 2019.

Author Bio:

Dr. Gary Arendash is the CEO and founder of NeuroEM. Dr. Arendash was a Full Professor and Research Professor at the University of South Florida for 30 years. During the last 6 years there, he directed the Florida Alzheimer’s Disease Research Center’s Animal Core. Dr. Arendash’s research expertise involves development of therapeutics against Alzheimer’s Disease. He has published over 100 peer-reviewed articles in first tier journals, including Science, Nature and the Journal of Alzheimer’s Disease – the last of which he has held the position of Senior Editor.

 

Rate this article
Share This Article

Share your Comments

Enrich and inform our Longevity Community. Your opinion matters!

Your email address will not be published. Required fields are marked *